Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FASENRA® Subcutaneous Injection 30 mg / 10mg Syringe Protocol of Specific Drug Use Result Study for Pediatric Patients

NCT06427876 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06427876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06427876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FASENRA® Subcutaneous Injection 30 mg / 10mg Syringe Protocol of Specific Drug Use Result Study for Pediatric Patients
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
July 16, 2024
Completion date
December 31, 2028
Enrollment
40 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

bronchial asthma